← Back to Search

Photosensitizer

Photodynamic Therapy for Mesothelioma and Lung Cancer

Phase 1
Waitlist Available
Led By Saikrishna Yendamuri
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects must have an Eastern Cooperative Oncology Group (ECOG) scale of 0-2.
Histologically confirmed malignant mesothelioma, non-small cell lung cancer (NSCLC) or other malignancies with pleural disease without distant disease.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the time of treatment (surgery + pdt) until death from any cause, assessed up to 3 years
Awards & highlights

Study Summary

This trial is testing a new way to measure the amount of light given during a cancer treatment called photodynamic therapy. They want to see if this new measure is more accurate than the current method and if it can help doctors decide if the treatment should be stopped or continued.

Who is the study for?
This trial is for adults with malignant mesothelioma, non-small cell lung cancer, or pleural disease who are undergoing surgery. They must be in fair to good physical condition (ECOG 0-2), agree to use birth control if applicable, and not have distant spread of the disease. People with low white blood cells or platelets, liver issues, uncontrolled illnesses like heart failure or infections, brain metastases, recent other treatments or investigational drugs can't join.Check my eligibility
What is being tested?
The study tests a light dosimetry system during photodynamic therapy using porfimer sodium on patients having surgery for certain cancers affecting the chest lining. It aims to determine how well this method works by measuring laser light used to activate the drug that may kill tumor cells.See study design
What are the potential side effects?
Possible side effects include reactions related to porfimer sodium which can cause sensitivity to light leading to skin damage when exposed to sunlight or bright indoor lights. Other risks involve typical surgical complications and potential harm from activated drugs targeting tumor cells.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am able to get out of my bed or chair and move around.
Select...
My cancer is confirmed to be in the lining of my chest but hasn't spread far.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the time of treatment (surgery + pdt) until death from any cause, assessed up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the time of treatment (surgery + pdt) until death from any cause, assessed up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
Secondary outcome measures
Anti tumor response
Overall survival (OS)
Progression-free survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (porfimer sodium, IO-PDT)Experimental Treatment3 Interventions
Participants receive porfimer sodium IV over 3-5 minutes and receive IO-PDT via a light dosimetry system 24-48 hours later.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Photodynamic Therapy
2014
Completed Phase 4
~460
Porfimer Sodium
2017
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Lumeda,Inc.UNKNOWN
Roswell Park Cancer InstituteLead Sponsor
402 Previous Clinical Trials
30,849 Total Patients Enrolled
2 Trials studying Mesothelioma
32 Patients Enrolled for Mesothelioma
Saikrishna YendamuriPrincipal InvestigatorRoswell Park Cancer Institute

Media Library

Porfimer Sodium (Photosensitizer) Clinical Trial Eligibility Overview. Trial Name: NCT03678350 — Phase 1
Mesothelioma Research Study Groups: Treatment (porfimer sodium, IO-PDT)
Mesothelioma Clinical Trial 2023: Porfimer Sodium Highlights & Side Effects. Trial Name: NCT03678350 — Phase 1
Porfimer Sodium (Photosensitizer) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03678350 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the federal government sanctioned Light Dosimetry for Intranoperative Therapy?

"As this is a Phase 1 trial with limited clinical evidence of safety and efficacy, our team has assigned Light Dosimetry for Intranoperative Therapy a score of 1."

Answered by AI

Is this research open to new applicants?

"Evidently, this clinical trial is currently open for enrollment. As per the latest edit from June 15th 2022, the experiment was initially posted on September 17th 2021."

Answered by AI

How many participants are currently involved in this scientific experiment?

"Affirmative. The records on clinicaltrials.gov demonstrate that recruitment for this trial is ongoing and was initiated on September 17th 2021, with the most recent update being made June 15th 2022. This study requires 12 participants from a single site to complete enrollment."

Answered by AI

Are there any precedents to the use of Light Dosimetry for Intranoperative Therapy?

"Currently, 5 studies concerning Light Dosimetry for Intranoperative Therapy are underway with none of them at the Phase 3 stage. Most trials related to this topic occur in Buffalo, New york however there is an additional 6 locations running these experiments."

Answered by AI
~3 spots leftby Apr 2025